Price$17.26-0.05 (-0.32%)
01:45 PM07:45 PM
News · 26 weeks66+157%
2025-12-142026-06-07
Mix3090d
- Insider17(57%)
- SEC Filings9(30%)
- Other2(7%)
- Earnings2(7%)
Latest news
25 items- SECNovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- INSIDERDirector Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERChief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Leung Gabriel sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 3% to 89,499 units (SEC Form 4) to satisfy withholding tax4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Stafford Kristin sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) (withholding obligation)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Ocean Allyson J sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 21% to 11,324 units (SEC Form 4) to cover withholding tax4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Scannell Timothy J sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 17% to 14,288 units (SEC Form 4) to satisfy withholding obligation4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hilleman Jeryl L sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 18% to 13,861 units (SEC Form 4) (for withholding tax)4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Vernon W Anthony sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 1% to 197,657 units (SEC Form 4) to satisfy tax liability4 - NovoCure Ltd (0001645113) (Issuer)
- INSIDERDirector Hung David sold $46,445 worth of Ordinary Shares (2,945 units at $15.77), decreasing direct ownership by 13% to 20,465 units (SEC Form 4) (for withholding tax)4 - NovoCure Ltd (0001645113) (Issuer)
- SECSEC Form DEFA14A filed by NovoCure LimitedDEFA14A - NovoCure Ltd (0001645113) (Filer)
- SECNovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NovoCure Ltd (0001645113) (Filer)
- SECSEC Form 10-Q filed by NovoCure Limited10-Q - NovoCure Ltd (0001645113) (Filer)
- PRNovocure Reports First Quarter 2026 Financial ResultsQuarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 Novocure (NASDAQ:NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "This was a very strong start to the year for Novocure and we are pleased w
- INSIDERDirector Vernon W Anthony exercised 21,500 units of Ordinary Shares at a strike of $11.39, increasing direct ownership by 12% to 200,602 units (SEC Form 4)4 - NovoCure Ltd (0001645113) (Issuer)
- SECAmendment: NovoCure Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - NovoCure Ltd (0001645113) (Filer)
- SECSEC Form DEFA14A filed by NovoCure LimitedDEFA14A - NovoCure Ltd (0001645113) (Filer)
- SECSEC Form DEF 14A filed by NovoCure LimitedDEF 14A - NovoCure Ltd (0001645113) (Filer)
NVCR FAQ
7 questionsWhat does NovoCure Limited do?
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial...Where does NVCR stock trade?
NovoCure Limited (NVCR) is listed on NASDAQ.What sector and industry is NVCR in?
NovoCure Limited operates in the Health Care sector, Medical/Dental Instruments industry.When did NovoCure Limited go public?
NovoCure Limited (NVCR) completed its IPO in 2015.What are analysts saying about NVCR?
NovoCure Limited has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1450.00 price target on 2025-07-25. Recent price targets range from $1450.00 to $4500.00.What companies are similar to NVCR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NVCR side-by-side with any of them on Quantisnow.How can I track NVCR on Quantisnow?
Quantisnow aggregates NovoCure Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCR to receive live email and push alerts on every new disclosure.